Title

An Open-Label Trial Of Aripiprazole Treatment In Dual Diagnosis Individuals: Safety And Efficacy

Keywords

Alcohol; Aripiprazole; Cocaine; Dual diagnosis; Marijuana

Abstract

This open-label study evaluated the safety and efficacy of aripiprazole in the treatment of 20 patients with co-morbid schizophrenia, schizoaffective disorder, or bipolar disorder and alcohol, cocaine, and/or marijuana use disorders. Primary outcomes were substance use, measured by the Timeline Followback, and score on the Clinical Global Impression scale for psychiatric and substance use symptoms. The data suggest that aripiprazole may reduce substance use and improve psychiatric symptoms in patients with co-morbid disorders; however, limitations are noted. Subsequent randomized studies are needed to further explore these findings. Copyright © Taylor & Francis Group, LLC.

Publication Date

1-1-2009

Publication Title

Journal of Dual Diagnosis

Volume

5

Issue

1

Number of Pages

83-96

Document Type

Article

Personal Identifier

scopus

DOI Link

https://doi.org/10.1080/15504260802620210

Socpus ID

61649093994 (Scopus)

Source API URL

https://api.elsevier.com/content/abstract/scopus_id/61649093994

This document is currently not available here.

Share

COinS